Inj, tremelimumab-actl, 1 mg
Products billed under this code include Imjudo.
Payment limit per 1 MG, by effective quarter, 3Q23 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Imjudo.
Payment limit per 1 MG, by effective quarter, 3Q23 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Imjudo | AstraZeneca Pharmaceuticals LP | 00310-4505-25 | 25 | $3,674.775 |
| Imjudo | AstraZeneca Pharmaceuticals LP | 00310-4535-30 | 300 | $44,097.30 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $146.991 | +$0.097 | 1 MG | Inj, tremelimumab-actl, 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $146.894 | +$3.666 | 1 MG | Inj, tremelimumab-actl, 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $143.228 | +$0.21 | 1 MG | Inj, tremelimumab-actl, 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $143.018 | +$2.121 | 1 MG | Inj, tremelimumab-actl, 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $140.897 | −$0.268 | 1 MG | Inj, tremelimumab-actl, 1 mg | v1, posted September 8, 2026 |
| 3Q25 | $141.165 | +$2.921 | 1 MG | Inj, tremelimumab-actl, 1 mg | v1, posted March 10, 2026 |
| 2Q25 | $138.244 | −$0.188 | 1 MG | Inj, tremelimumab-actl, 1 mg | v1, posted March 10, 2026 |
| 1Q25 | $138.432 | +$2.984 | 1 MG | Inj, tremelimumab-actl, 1 mg | v1, posted December 19, 2025 |
| 4Q24 | $135.448 | −$0.115 | 1 MG | Inj, tremelimumab-actl, 1 mg | v1, posted June 11, 2025 |
| 3Q24 | $135.563 | −$0.183 | 1 MG | Inj, tremelimumab-actl, 1 mg | v1, posted June 11, 2025 |
| 2Q24 | $135.746 | −$0.347 | 1 MG | Inj, tremelimumab-actl, 1 mg | v1, posted March 11, 2025 |
| 1Q24 | $136.093 | −$0.213 | 1 MG | Inj, tremelimumab-actl, 1 mg | v1, posted December 19, 2024 |
| 4Q23 | $136.306 | −$0.254 | 1 MG | Inj, tremelimumab-actl, 1 mg | v1, posted October 10, 2024 |
| 3Q23 | $136.56 | – | 1 MG | Inj, tremelimumab-actl, 1 mg | v1, posted June 5, 2024 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.